SOURCE: Xtalks

Xtalks Webinars

June 08, 2017 07:30 ET

Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - June 08, 2017) - In this presentation, Dr. Michelle Mack, Global Director of Scientific Engagement at Crown Bioscience Inc. will outline the latest in vivo Immuno-Oncology models and what to consider when choosing the proper model. She will also discuss how these models are used to investigate immunotherapeutics combined with other treatment modalities, which correspond to current clinical investigations.

Recent regulatory approvals and fast-track designations have signified the coming of age of cancer immunotherapy as a treatment paradigm. Among experimental immunotherapies, monoclonal antibodies targeting immune regulation checkpoints e.g. cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are demonstrating impressive clinical benefits in a range of cancer types. However, development of effective new immunotherapeutics still face many challenges. Researchers are still unsure why some patients and diseases benefit from these treatments while others do not. It is also currently unknown how to maximize the benefits from these agents through combination therapy approaches or between targeting different immune checkpoints.

Determining the best experimental immunotherapy model is a key factor in answering these questions and developing better treatments. At present, most commonly used experimental cancer models comprise of human tumors grown in immunocompromised mice, derived from either in vitro immortalized cancer cells (cell line derived xenografts) or patient tumors (patient-derived xenografts, or PDX). The lack of functional immunity in these immunodeficient mice has significantly hindered the research and development of new immunotherapy agents. Syngeneic and genetically engineered mouse models (GEMM) with functional murine immunity are available; however, each has their own benefits and limitations. As new models are also developed, with different capabilities, choosing the correct and relevant preclinical model is critical, particularly to recapitulate clinical treatments including combination therapies.

Join Dr. Mack on Thursday, June 22, 2017 at 11am EDT (4pm BST/UK) for an informative session. For details or to register for this complimentary event, visit: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

For information about hosting a webinar visit

Image Available:

Contact Information